Clinical Trials Logo

Lymphocytic Leukemia, Chronic clinical trials

View clinical trials related to Lymphocytic Leukemia, Chronic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02292225 Terminated - Clinical trials for Lymphocytic Leukemia, Chronic

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Start date: February 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.

NCT ID: NCT01283386 Terminated - Clinical trials for Lymphocytic Leukemia, Chronic

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Start date: April 27, 2011
Phase: Phase 4
Study type: Interventional

This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell chronic lymphocytic leukemia and unfavorable somatic status. Participants were randomized to receive Mabthera (375 mg/m2 intravenously [IV] Day 1 of Cycle 1, 500 mg/m2 IV Day 1 Cycles 2-6) with either fludarabine (20 mg/m2 IV or 32 mg/m2 orally Days 1-3) and cyclophosphamide (150 mg/m2 IV or orally Days 1-3) or with chlorambucil (10 mg/m2 orally Days 1-7) for 6 cycles of 28 days. Anticipated time on study treatment was 24 weeks.

NCT ID: NCT01271010 Terminated - Clinical trials for Lymphocytic Leukemia, Chronic

A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

Start date: June 17, 2011
Phase: Phase 4
Study type: Interventional

This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.